Previous Close | 18.49 |
Open | 18.50 |
Bid | 18.68 x 100 |
Ask | 18.83 x 100 |
Day's Range | 18.17 - 18.92 |
52 Week Range | 15.13 - 32.53 |
Volume | |
Avg. Volume | 848,496 |
Market Cap | 1.705B |
Beta (5Y Monthly) | 1.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.77 |
Earnings Date | Nov 04, 2024 - Nov 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 43.33 |
CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. RCKT) on Monday reported a loss of $69.6 million in its second quarter. The Cranbury, New Jersey-based company said it had a loss of 74 cents per share.
Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund declined 2.55% (Institutional Shares) in the quarter compared to a 1.02% decline for the Russell 3000 Health Care Index (benchmark) and a 3.22% gain for the Russell […]
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.